Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Non-invasive diagnosis of pleural malignancies: the role of tumour markers.

van den Heuvel MM, Korse CM, Bonfrer JM, Baas P.

Lung Cancer. 2008 Mar;59(3):350-4. Epub 2007 Oct 22.

PMID:
17933420
2.

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.

Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272.

PMID:
18154821
3.

Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.

Fuhrman C, Duche JC, Chouaid C, Abd Alsamad I, Atassi K, Monnet I, Tillement JP, Housset B.

Clin Biochem. 2000 Jul;33(5):405-10.

PMID:
11018693
4.

Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS.

Hegmans JP, Veltman JD, Fung ET, Verch T, Glover C, Zhang F, Allard WJ, T'Jampens D, Hoogsteden HC, Lambrecht BN, Aerts J.

Technol Cancer Res Treat. 2009 Oct;8(5):323-32.

PMID:
19754208
5.

Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.

Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):646-50. doi: 10.1158/1055-9965.EPI-08-0422. Epub 2009 Feb 3.

6.

Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.

Filiberti R, Parodi S, Libener R, Ivaldi GP, Canessa PA, Ugolini D, Bobbio B, Marroni P.

Med Oncol. 2013 Jun;30(2):543. doi: 10.1007/s12032-013-0543-6. Epub 2013 Mar 27.

PMID:
23532816
7.

[Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].

Amati M, Tomasetti M, Scartozzi M, Mariotti L, Ciuccarelli M, Valentino M, Governa M, Santarelli L.

G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):335-8. Italian.

PMID:
18409713
8.

MESOMARK: a potential test for malignant pleural mesothelioma.

Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY.

Clin Chem. 2007 Apr;53(4):666-72. Epub 2007 Feb 8.

9.

Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.

Ferro P, Canessa PA, Battolla E, Dessanti P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2013 Jun;33(6):2707-13.

PMID:
23749930
10.

Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.

Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, Raithel HJ, Kraus T, Brüning T.

Arch Toxicol. 2011 Mar;85(3):185-92. doi: 10.1007/s00204-010-0580-2. Epub 2010 Aug 25.

PMID:
20737138
11.

Value of tumour and inflammatory markers in lung cancer.

Oremek GM, Sauer-Eppel H, Bruzdziak TH.

Anticancer Res. 2007 Jul-Aug;27(4A):1911-5.

12.
13.

Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.

Amati M, Tomasetti M, Scartozzi M, Mariotti L, Alleva R, Pignotti E, Borghi B, Valentino M, Governa M, Neuzil J, Santarelli L.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):163-70. doi: 10.1158/1055-9965.EPI-07-0607.

14.

Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.

Gaspar MJ, De Miguel J, García Díaz JD, Díez M.

Anticancer Res. 2008 Sep-Oct;28(5B):2947-52.

15.

Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions.

Alataş F, Alataş O, Metintaş M, Colak O, Harmanci E, Demir S.

Lung Cancer. 2001 Jan;31(1):9-16.

PMID:
11162861
16.

Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.

Luo L, Shi HZ, Liang QL, Jiang J, Qin SM, Deng JM.

Respir Med. 2010 Jan;104(1):149-56. doi: 10.1016/j.rmed.2009.05.017. Epub 2009 Nov 30. Review.

17.

Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.

Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P.

Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60. Epub 2006 Feb 2.

PMID:
16456138
18.

Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.

Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.

J Thorac Oncol. 2013 Jul;8(7):947-51. doi: 10.1097/JTO.0b013e31828f696b.

19.

Osteopontin is not a specific marker in malignant pleural mesothelioma.

Paleari L, Rotolo N, Imperatori A, Puzone R, Sessa F, Franzi F, Meacci E, Camplese P, Cesario A, Paganuzzi M.

Int J Biol Markers. 2009 Apr-Jun;24(2):112-7.

PMID:
19634115
20.

CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.

Pavićević R, Bubanović G, Franjević A, Stancić-Rokotov D, Samarzija M.

Coll Antropol. 2008 Jun;32(2):485-98.

PMID:
18756899
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk